181 related articles for article (PubMed ID: 10454217)
1. Pharmacology of antisense oligonucleotide inhibitors of protein expression.
Cooper SR; Taylor JK; Miraglia LJ; Dean NM
Pharmacol Ther; 1999; 82(2-3):427-35. PubMed ID: 10454217
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of Antisense Drugs.
Bennett CF; Baker BF; Pham N; Swayze E; Geary RS
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():81-105. PubMed ID: 27732800
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
4. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.
Shen X; Corey DR
Nucleic Acids Res; 2018 Feb; 46(4):1584-1600. PubMed ID: 29240946
[TBL] [Abstract][Full Text] [Related]
5. Splice-switching antisense oligonucleotides as therapeutic drugs.
Havens MA; Hastings ML
Nucleic Acids Res; 2016 Aug; 44(14):6549-63. PubMed ID: 27288447
[TBL] [Abstract][Full Text] [Related]
6. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
7. Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue.
Golden T; Dean NM; Honkanen RE
Microcirculation; 2002 Jan; 9(1):51-64. PubMed ID: 11896559
[TBL] [Abstract][Full Text] [Related]
8. Progress toward therapy with antisense-mediated splicing modulation.
Du L; Gatti RA
Curr Opin Mol Ther; 2009 Apr; 11(2):116-23. PubMed ID: 19330717
[TBL] [Abstract][Full Text] [Related]
9. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
Branch AD
Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Antisense Oligonucleotides Are Coming of Age.
Bennett CF
Annu Rev Med; 2019 Jan; 70():307-321. PubMed ID: 30691367
[TBL] [Abstract][Full Text] [Related]
12. Making antisense of splicing.
Garcia-Blanco MA
Curr Opin Mol Ther; 2005 Oct; 7(5):476-82. PubMed ID: 16248283
[TBL] [Abstract][Full Text] [Related]
13. Antisense strategies.
Crooke ST
Curr Mol Med; 2004 Aug; 4(5):465-87. PubMed ID: 15267220
[TBL] [Abstract][Full Text] [Related]
14. [Synthetic oligonucleotides and their application in gene therapy].
Iribarren AM
Medicina (B Aires); 1995; 55(3):263-6. PubMed ID: 8544726
[TBL] [Abstract][Full Text] [Related]
15. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies.
McClorey G; Wood MJ
Curr Opin Pharmacol; 2015 Oct; 24():52-8. PubMed ID: 26277332
[TBL] [Abstract][Full Text] [Related]
16. Functional genomics and target validation approaches using antisense oligonucleotide technology.
Dean NM
Curr Opin Biotechnol; 2001 Dec; 12(6):622-5. PubMed ID: 11849945
[TBL] [Abstract][Full Text] [Related]
17. Antisense therapeutics: is it as simple as complementary base recognition?
Agrawal S; Kandimalla ER
Mol Med Today; 2000 Feb; 6(2):72-81. PubMed ID: 10652480
[TBL] [Abstract][Full Text] [Related]
18. Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.
Ittig D; Liu S; Renneberg D; Schümperli D; Leumann CJ
Nucleic Acids Res; 2004; 32(1):346-53. PubMed ID: 14726483
[TBL] [Abstract][Full Text] [Related]
19. Medicinal chemistry of antisense oligonucleotides--future opportunities.
Cook PD
Anticancer Drug Des; 1991 Dec; 6(6):585-607. PubMed ID: 1772571
[TBL] [Abstract][Full Text] [Related]
20. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
